Sickle Cell Disease Comprehensive Care Act
- Bill Number
- H.R. 5178
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-09-08: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-06-30T08:06:33Z
AI-Generated Summary
Purpose
The Sickle Cell Disease Comprehensive Care Act (H.R. 5178) aims to expand access to coordinated healthcare services for people with sickle cell disease (SCD) under Medicaid. It allows states to create specialized "health homes"—centralized care coordination models—to provide comprehensive support, including medical, dental, and vision services, to improve health outcomes for this population.
Key Provisions
- Expansion of Health Homes: Starting January 1, 2026, states can offer Medicaid health home services to eligible individuals with SCD, in addition to those with other chronic conditions. A health home coordinates care across providers to manage a person's overall health needs.
- SCD-Focused State Plans: States may submit amendments to their Medicaid plans specifically targeting SCD patients. These must include dental and vision services for enrolled individuals, even if the state does not provide these to other Medicaid recipients (overriding usual rules on service comparability).
- Reporting Requirements: States with SCD-focused plans must submit a report to the Secretary of Health and Human Services (HHS) by the end of the 8th fiscal year quarter after approval. The report covers:
- Quality of care, focusing on recovery outcomes.
- Access to healthcare.
- Total healthcare expenditures.
The HHS Secretary will define specific measures for these areas.
- Best Practices Guidance: By June 30, 2026, the Centers for Medicare & Medicaid Services (CMS) must publish online best practices for designing and implementing SCD-focused health homes. This guidance will draw from clinical guidelines by medical experts and input from SCD providers and patient advocacy groups.
- Definitions:
- Eligible individual with SCD: A person eligible for Medicaid who has SCD (diagnosed via newborn screening or genetic testing) and may or may not have previously used health home services.
- Sickle cell disease: An inherited blood disorder where red blood cells become misshapen due to inheriting a sickle cell gene from both parents.
Significant Changes to Existing Law
- Amends Section 1945 of the Social Security Act, which previously authorized health homes only for people with chronic conditions (like diabetes or heart disease).
- Introduces SCD as a standalone eligibility category for health homes, allowing targeted state programs without requiring co-existing chronic conditions.
- Mandates dental and vision coverage in SCD-focused programs, bypassing standard Medicaid rules that limit these services or require uniform application across all beneficiaries.
- Adds new reporting and best practices requirements, enhancing federal oversight and standardization for SCD care under Medicaid.
Potential Impacts
- On Citizens: Individuals with SCD—often from underserved communities—could gain better access to coordinated care, potentially reducing pain crises, hospitalizations, and long-term complications. Including dental and vision services addresses common SCD-related issues like oral pain and eye damage.
- On Government Agencies: State Medicaid programs gain flexibility to tailor services but face new reporting burdens. CMS and HHS will need resources to develop measures, guidance, and review amendments, possibly increasing administrative costs. Overall Medicaid spending may rise short-term due to expanded services but could decrease long-term through better health management.
- On International Relations: No direct impacts, as this is a domestic healthcare policy focused on U.S. Medicaid.
Main Stakeholders Affected
- Individuals with SCD and Families: Primary beneficiaries, gaining targeted care access.
- State Medicaid Agencies: Responsible for implementing optional programs, reporting data, and ensuring service provision.
- Healthcare Providers: Including doctors, dentists, and vision specialists serving SCD patients, with opportunities for coordinated care roles.
- Federal Agencies (CMS and HHS): Oversee approvals, define standards, and publish resources.
- Patient Advocacy Organizations and Medical Societies: Involved in consultations for best practices and may support program rollout.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens Medicaid's role in addressing specific diseases by allowing exceptions to comparability rules (ensuring services are provided equally across similar groups), potentially setting precedents for other targeted health programs. Reporting requirements promote accountability without mandating participation, respecting state flexibility under federalism.
- Constitutional: Aligns with Congress's authority to regulate interstate commerce and spend for the general welfare (via Medicaid funding); no apparent conflicts with equal protection or due process, as it expands voluntary benefits for a defined medical group.
- Political: Bipartisan support (evident from diverse cosponsors) highlights focus on health equity for a disproportionately affected minority population. Could influence future legislation on rare diseases or Medicaid innovations, but implementation depends on state adoption and federal funding levels.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (34)
Rep. Davis, Danny K. [D-IL-7], Rep. Carter, Earl L. "Buddy" [R-GA-1], Rep. Figures, Shomari [D-AL-2], Rep. Bilirakis, Gus M. [R-FL-12], Rep. Johnson, Julie [D-TX-32], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. McIver, LaMonica [D-NJ-10], Rep. Fields, Cleo [D-LA-6], Rep. Green, Al [D-TX-9], Rep. Gottheimer, Josh [D-NJ-5], Rep. Tlaib, Rashida [D-MI-12], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Jackson, Jonathan L. [D-IL-1], Rep. Davis, Donald G. [D-NC-1], Rep. Soto, Darren [D-FL-9], Rep. Budzinski, Nikki [D-IL-13], Rep. Sewell, Terri A. [D-AL-7], Rep. Thompson, Bennie G. [D-MS-2], Rep. Moulton, Seth [D-MA-6], Rep. Carson, André [D-IN-7], Rep. Thanedar, Shri [D-MI-13], Rep. Ivey, Glenn [D-MD-4], Rep. McBride, Sarah [D-DE-At Large], Rep. Vindman, Eugene Simon [D-VA-7], Rep. Friedman, Laura [D-CA-30], Rep. Jayapal, Pramila [D-WA-7], Rep. Wilson, Joe [R-SC-2], Del. Plaskett, Stacey E. [D-VI-At Large], Rep. Moore, Gwen [D-WI-4], Rep. DelBene, Suzan K. [D-WA-1], Rep. Aguilar, Pete [D-CA-33], Rep. Conaway, Herbert C. [D-NJ-3], Rep. Adams, Alma S. [D-NC-12], Rep. Carbajal, Salud O. [D-CA-24]
Recent Actions
- 2025-09-08: Referred to the House Committee on Energy and Commerce.
- 2025-09-08: Introduced in House
- 2025-09-08: Introduced in House
Bill Versions
- Sickle Cell Disease Comprehensive Care Act — issued 2025-09-08 — PDF (6 pages)